Ascendis Pharma A/S
NASDAQ:ASNDBiotechnology
-$0.05 today
- Market cap
- $17.73B
- Beta
- 0.39
- P/E (TTM)
- 24.5
- EPS (TTM)
- $8.21
Volume 0.57M
Average 0.64M
ASND Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Ascendis Pharma A/SNASDAQ: ASND
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of €67.04M rose 0.2% year over year, ahead of the -10.0% change in trailing-twelve-month research & development. Sequentially, it fell 10.2% from the prior quarter. Over 3 fiscal years it compounded at -9.3% a year.
Context
- Research & development amounted to 41.0% of revenue in FY2025, down 43.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.2% holds above the trailing-twelve-month pace of -10.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 283.5M EUR
- Year-over-year change
- -7.7%
- 4-year CAGR
- -1.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 283.5M | -7.7% |
| FY2024 | 2024-12-31 | 307M | -25.7% |
| FY2023 | 2023-12-31 | 413.45M | +8.9% |
| FY2022 | 2022-12-31 | 379.62M | +28.3% |
| FY2021 | 2021-12-31 | 295.87M | — |
Research & Development vs competitors
How ASND compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.0% is the lowest of 11, against a peer median of +30.5%.
- Research & development amounts to 22.7% of revenue for ASND, versus a peer median of 33.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $181.1B USD | +19955.1% | +12.4% | 17.6% | |
| LTM Sep 2026 | $1.23B USD | +30.7% | +29.9% | 33.3% | |
| LTM Jun 2026 | $860.85M USD | +30.4% | +24.7% | 75.7% | |
| LTM Mar 2026 | $770.95M USD | +12.5% | +2.0% | 115.2% | |
| LTM Jun 2026 | $551.5M USD | +6.0% | +19.4% | 17.5% | |
| LTM Sep 2026 | €274.3M EUR | -10.0% | -9.3% | 22.7% | |
| LTM Jun 2026 | $253.86M USD | +1.2% | +24.8% | 30.6% | |
| LTM Mar 2026 | $144.07M USD | +45.7% | +21.0% | 449.1% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $132.66M USD | +56.0% | — | 137.8% |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $101.27M USD | +35.7% | +54.7% | — |
| LTM Mar 2026 | $32.2M USD | +26.3% | +14.1% | 10.2% | |
| Peer median (excluding ASND) | — | +30.5% | +21.0% | 33.3% | |
Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.78M | 51.17M | 266.72M | 363.64M | 691.71M |
| Cost of Revenue | 3.52M | 12.14M | 44.4M | 44.26M | 103.18M |
| Gross Profit | 4.26M | 39.04M | 222.32M | 319.38M | 588.53M |
| Gross Margin | 54.7% | 76.3% | 83.4% | 87.8% | 85.1% |
| Research & Development | 295.87M | 379.62M | 413.45M | 307M | 283.5M |
| Selling, General & Admin | 160.18M | 215.85M | 258.79M | 284.55M | 435.92M |
| Operating Expenses | 456.05M | 600.85M | 677.86M | 598.15M | 719.42M |
| Depreciation & Amortization | 15.39M | 17.96M | 18.91M | 17.71M | 17M |
| EBITDA | (364.64M) | (529.18M) | (411.17M) | (290.02M) | (109.8M) |
| EBITDA Margin | -4688.1% | -1034.1% | -154.2% | -79.8% | -15.9% |
| Operating Income | (451.79M) | (561.81M) | (455.54M) | (278.76M) | (130.89M) |
| Operating Margin | -5808.6% | -1097.9% | -170.8% | -76.7% | -18.9% |
| Interest Income | 692K | 7.43M | 16.86M | 14.36M | 14.7M |
| Interest Expense | 3.91M | 30.68M | 44.07M | 65.5M | 77.46M |
| Other Income / Expenses | 67.85M | (16M) | (18.6M) | (94.48M) | (73.37M) |
| Income Before Tax | (383.94M) | (577.82M) | (474.14M) | (373.24M) | (204.26M) |
| Pre-Tax Margin | -4936.3% | -1129.1% | -177.8% | -102.6% | -29.5% |
| Income Tax Expense | (367K) | 5.38M | 7.3M | 4.84M | 14.78M |
| Net Income | (383.58M) | (583.19M) | (481.45M) | (378.08M) | (219.03M) |
| Net Margin | -4931.6% | -1139.6% | -180.5% | -104.0% | -31.7% |
| EPS (Basic) | (7.00) | (10.40) | (8.55) | (6.53) | (3.62) |
| EPS (Diluted) | (7.00) | (10.40) | (8.55) | (6.53) | (3.62) |
| Weighted Avg Shares | 54.77M | 56.07M | 56.29M | 57.89M | 60.61M |
| Weighted Avg Shares (Diluted) | 54.77M | 56.07M | 56.29M | 57.89M | 60.61M |
Ascendis Pharma A/S
NASDAQ:ASND
Intrinsic Alpha fair value
Locked
Current Price
$270.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.